Discover a recent study that revealed that interstitial cystitis patients were older, predominantly female, and exhibited ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

Distinct phenotypic and urine biological characteristics are seen for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with a history of ulcerative Hunner lesions (UIC) and those ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.